drugset / Trial / NCT02705989

Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects

NCT02705989

Phase 1 Completed 439 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics, and pharmacodynamics following single and multiple ascending oral doses of BMS-986195 in healthy subjects, and to assess the relative bioavailability of two formulations of BMS-986195 with or without food.

Timeline

Start
2016-08-18
Primary completion
2017-08-16
Completion
2017-08-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Branebrutinib Small molecule Oral

Indications